Investigational Intratumoral Cancer Immunotherapy
OncoSec’s VLA: Visceral Lesion Applicator
Clinical trial currently recruiting patients with TNBC
News & Events
Designed to Arm the Immune System to Fight Cancer
We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.
Our core technology platform continues to advance through clinical trials for various cancers
Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer